SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Zcash is a decentralized and open-source cryptocurrency that offers privacy and selective transparency of transactions. Zcash payments are published on a public blockchain, but the sender, recipient, and amount of a transaction remain private.  Zcash is based on peer-reviewed cryptographic research, and built by a security-specialized engineering team on an open source platform based on Bitcoin Core's battle-tested codebase. Our improvement over Bitcoin is the addition of privacy. Zcash uses advanced cryptographic techniques, namely zero-knowledge proofs, to guarantee the validity of transactions without revealing additional information about them.  How Zcash works  Zcash encrypts the contents of shielded transactions. Since the payment information is encrypted, the protocol uses a novel cryptographic method to verify their validity.  Zcash uses a zero-knowledge proof construction called a zk-SNARK, developed by our team of experienced cryptographers based on recent breakthroughs in cryptography. These constructions allow the network to maintain a secure ledger of balances without disclosing the parties or amounts involved. Instead of publicly demonstrating spend-authority and transaction values, the transaction metadata is encrypted and zk-SNARKs are used to prove that nobody is cheating or stealing.  Zcash also enables users to send public payments which work similarly to Bitcoin. With the support for both shielded and transparent addresses, users can choose to send Zcash privately or publicly. Zcash payments sent from a shielded address to a transparent address reveal the received balance, while payments from a transparent address to a shielded address protect the receiving value.   Check out CoinBureau for guide on What is ZCash.

Zcash

Zcash is surging, sparking discussions about its potential as 'the better Bitcoin' due to its privacy features. Community members are weighing in on whether to hold long-term or take profits amidst the impressive run, while some speculate on possible pullbacks. The focus remains on ZEC's unique features and potential for further growth in the crypto space.

JasmyCoin is based on the ERC 20 standard. The token can also be used by an unspecified number of individuals and businesses to transfer tokens using digital devices as proof of value exchange or payment for services. By not limiting its usability, the token can have a wide range of purposes.

JasmyCoin

JasmyCoin is trending as the community debates the implications of the new JUNCTION mechanism and its potential impact on the Jasmy ecosystem. Some believe JANCTION will drive demand for JASMY and strengthen its utility, while others express concerns that it could overshadow or replace JasmyCoin. Bullish sentiment centers around the idea that JANCTION represents a significant step in the development of the Jasmy ecosystem.

Welcome to SLAP – The Only Coin That Slaps Harder Than Your Moms  Tired of coins that claim they SLAP but are nothing but limp wrists? SLAP is here to SLAP some sense into the crypto space.  Founded by the Flutter of Five Fingers and powered by the Prancing of the Pried Palm, SLAP isn’t just another coin—it’s an attitude.  We’re not here to talk roadmaps, utility, or world peace. We’re here to SLAP charts, SLAP the haters, and SLAP our way to the top. No VC suits, no corporate nonsense—just raw, unfiltered internet culture with a side of “did we just do that?  ”So load your wallet, mute your financial advisor, and get ready to ride the most unhinged meme rocket. Open up your hands, and start swingin'. You never know what you could hit.  SLAP: It’s not a coin. It’s a lifestyle.

Slap

Slap is trending as the community rallies around the project, expressing bullish sentiment and celebrating milestones like surpassing 500 watchers. Discussions also highlight the project's consistency and its mission to spread Web3 knowledge, with some users emphasizing the importance of community and shared success using the tag $WAGMI. The coin is associated with several other crypto coins: $BTC $ETH $SOL $BROKE $CAW $RAGE.

Internet Computer (IC) is the world’s first blockchain that is capable of running at web speed at unrestrictive capacities. Built by the DFINITY Foundation, IC aims to recreate the web by supporting smart contract development at scale and changing the way people can interact using web services. Internet Computer aims to extend the public internet, so that it can be the world’s computing platform, in a decentralized manner. Internet Computer sets to revolutionalize the design of the crypto economy, with an aim to overhaul traditional software services.   The project was founded in October 2016 by Dominic WIllams and have raised a total of $121 million from investors such as Adreessen Horowitz, Polychain Capital, Multicoin Capital and such. On May 10, 2021, DFINITY launched the Internet Computer into the public domain, marking it a major milestone for ICP as it means the internet now functions as a decentralised global computer. This is marked by the release of all of the Internet Computer’s source code into the public domain, as well as ICP utility token that allows tens of thousands of community members to govern the Internet Computer network.  ICP is Internet Computer's native token. It plays three prominent roles:  1. Network Governance: Users that participate in the governance will be rewarded with ICPI 2. Production of Cycles for Compute: ICP can be converted into cycles where it is used as the transaction fee to access the network. Cycles are burned after used. 3. Rewarding Users: ICP is used as the rewards to incentivize users to participate in the network such as securing the network.

Internet Computer

ICP is trending as the community discusses its potential within the AI crypto space and its ability to challenge established cloud computing models. Bullish sentiment is fueled by recent price action and increasing volume, with some comparing it to previous runs of other altcoins. The conversations revolve around its unique technology and the possibility of significant long-term growth.

Direxion Shares ETF Trust - Direxion Daily S&P Biotech Bull 3X Shares

Direxion Daily S&P Biotech Bull 3X Shares

LABU is trending amid mixed market signals and sector-specific developments, as traders weigh potential catalysts. Community members are actively discussing technical indicators and trading strategies, particularly around key resistance levels. The broader conversation includes the impact of economic data, potential government actions, and the ever-present uncertainty in the biotech sector.

What Is Tezos (XTZ)?   Tezos is a high-performing blockchain and open-source platform for assets and applications, with a strong focus on code security, on-chain governance, and decentralization. Tezos 2.0, the upcoming step in the evolution of Tezos, aims to improve scalability (via layer 2s), composability, and to implement support to mainstream programming languages (like Javascript, Typescript, Python, and many others).   Initially built with formal verification in mind, the Tezos protocol enables builders to avoid bugs when developing smart contracts, making it particularly suited to applications that require a high degree of security and certainty.   Tezos’ LPoS (Liquid Proof-of-Stake) consensus mechanism enables any stakeholder to take part, directly or by delegation, in the consensus process, and to be rewarded for securing the network. Rather uniquely, Tezos’ on-chain governance system also enables stakeholders to create and vote on protocol upgrade proposals. This pioneering system allows the protocol to self-amend and upgrade itself without leading to a split (or fork) in the blockchain, empowering the community without slowing down innovation.   First proposed in 2014 and launched in 2018, the Tezos Mainnet has a proven track record of running uninterrupted ever since, having earned a strong reputation for technical excellence and a supportive community.    Who Are the Founders of Tezos? Tezos was conceived by Arthur and Kathleen Breitman in a 2014 white paper under the pseudonym L.M. Goodman in a nod to Satoshi Nakamoto, referencing a journalist who had misidentified the creator of Bitcoin.   In a previous paper, the Breitmans had argued that Bitcoin's biggest shortcomings were the lack of a governance process that invited contributions from its community of users, cost and centralization issues raised by its proof-of-work system, the limited expressiveness of its programming language which didn’t allow for smart contracts, and security

Tezos

Tezos (XTZ) is trending amid volatile price action, sparking heated debates about its potential. The community is divided, with some calling it a "sucker coin" ripe for pump and dumps, while others express optimism for future growth and highlight staking rewards. Discussions also include the circulating supply and potential catalysts like upcoming FED rate cuts.

DaVita, Inc. engages in the provision of medical care services. It operates through the following two segments: US Dialysis and Related Lab Services, and Other-Ancillary Services and Strategic Initiatives. The US Dialysis and Related Lab Services segment offers kidney dialysis services in the United States for patients suffering from chronic kidney failure. The Other-Ancillary Services and Strategic Initiatives segment consist primarily of pharmacy services, disease management services, vascular access services, clinical research programs, physician services, direct primary care, end stage renal disease seamless care organizations, and comprehensive care. The company was founded in 1994 and is headquartered in Denver, CO.

DaVita Inc

DaVita Inc (DVA) is trending due to community discussion around mortality rates and the potential adoption of DefenCath, an infection-reducing product, versus cost-cutting measures. Some investors express concern over the company's focus on share repurchases rather than investing in solutions to reduce catheter-related bloodstream infections (CRBSIs). Additionally, TDAPA (Transitional Drug Add-on Payment Adjustment) policy proposals and Q3 2025 earnings are focal points in community discussions.

Direxion Shares ETF Trust - Direxion Daily S&P Biotech Bear 3X Shares

Direxion Daily S&P Biotech Bear 3X Shares

LABD is trending as traders discuss potential catalysts for a reversal, including government shutdowns and trade tensions, while acknowledging the strong upward trend of XBI. Community members are weighing strategies like averaging down versus waiting for more concrete signs of a market shift, with some expressing frustration at the ETF's continued decline. The broader biotech sector's performance and overall market conditions remain key talking points.

Elastic NV is a data analytics company, which engages in the provision of open-source search and analytics engine services. It operates through the United States, the Netherlands, United Kingdom, India, and Rest of World geographical segments. The company was founded by Shay Banon, Uri Boness, Steven Schuurman, and Simon Willnauer on February 9, 2012 and is headquartered in San Francisco, CA.

Elastic N.V

Elastic is trending as investors weigh its potential in the AI space ahead of upcoming earnings, with some highlighting its relevance in retrieval-augmented generation (RAG). A recent analyst day revealed a $500 million share repurchase program and increased revenue outlook for fiscal year 2026, leading to price target increases, though some remain skeptical about its profitability and the CEO's compensation.

BtcUSD is a completely decentralized stablecoin issued and managed by BTCFi, a platform where users can deposit Bitcoin of various formats to use as collaterals. BtcUSD offers Bitcoin holders the opportunity to generate additional yields with their Bitcoin positions through DeFi usage.

Bitcoin USD (BTCFi)

Bitcoin is seeing active discussion regarding potential resistance and support levels as the price consolidates, with some traders anticipating a volatility spike. Community members are weighing bullish and bearish scenarios, referencing Elliott Wave analysis and Fibonacci levels to predict future price movements. Others point to increasing institutional ownership and historical patterns to support a long-term bullish outlook.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Y Intercept Hong Kong Ltd Takes $475,000 Position in Trevi Therapeutics, Inc. $TRVI

Y Intercept Hong Kong Ltd acquired a new position in shares of Trevi Therapeutics, Inc. (NASDAQ:TRVI - Free Report) during the 2nd quarter, according to its most recent 13F filing with the Securities...

Trevi Therapeutics to Report Third Quarter 2025 Financial Results and Provide a Corporate Update on November 13, 2025

Trevi Therapeutics to Report Third Quarter 2025 Financial Results and Provide a Corporate Update on November 13, 2025 Trevi Therapeutics to Report Third Quarter 2025 Financial Results and Provide a...

Trevi Therapeutics to Participate in Stifel 2025 Healthcare Conference

Trevi Therapeutics to Participate in Stifel 2025 Healthcare Conference Trevi Therapeutics to Participate in Stifel 2025 Healthcare Conference PR Newswire NEW HAVEN, Conn., Nov. 4, 2025 Fireside Chat...

Wall Street Analysts Predict a 231.05% Upside in Trevi Therapeutics (TRVI): Here's  What You Should Know

The mean of analysts' price targets for Trevi Therapeutics (TRVI) points to a 231.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Wall Street Analysts See a 195.05% Upside in Trevi Therapeutics (TRVI): Can the Stock Really Move This High?

Trevi Therapeutics Completes Enrollment for Phase 2b CORAL Trial of Haduvio in Idiopathic Pulmonary Fibrosis Patients with Chronic Cough

Trevi Therapeutics Completes Enrollment for Phase 2b CORAL Trial of Haduvio in Idiopathic Pulmonary Fibrosis Patients with Chronic Cough Trevi Therapeutics Completes Enrollment for Phase 2b CORAL...

Trevi Therapeutics to Participate in Upcoming February Investor Conferences

Trevi Therapeutics to Participate in Upcoming February Investor Conferences Trevi Therapeutics to Participate in Upcoming February Investor Conferences PR Newswire NEW HAVEN, Conn., Jan. 30, 2025 NEW...

Trevi Therapeutics Announces Company Updates Ahead of 14th Annual LifeSci Partners Corporate Access Event Held During the J.P. Morgan Healthcare Conference

Trevi Therapeutics Announces Company Updates Ahead of 14th Annual LifeSci Partners Corporate Access Event Held During the J.P. Morgan Healthcare Conference Trevi Therapeutics Announces Company...

Trevi Therapeutics Announces Pricing of $50 Million Underwritten Offering

Trevi Therapeutics Announces Pricing of $50 Million Underwritten Offering Trevi Therapeutics Announces Pricing of $50 Million Underwritten Offering PR Newswire NEW HAVEN, Conn., Dec. 16, 2024 NEW...

Shares of Trevi Therapeutics Inc. rose over 6% on Friday morning, building on momentum from the previous session when the stock hit over two-year intraday highs.&nbsp;The surge came as heavy retail buzz pushed the ticker to prominence on Stocktwits, where message volume spiked over 4,900% on Thursday.The company announced that its phase 2b study of Haduvio, an investigational therapy for idiopathic pulmonary fibrosis (IPF) with chronic cough, has achieved 75% of its enrollment target of 160 patients.&nbsp;An independent statistician confirmed the sample size following a re-estimation analysis, ensuring the trial’s design remains statistically robust.&nbsp;The analysis involved treating 80 patients with Haduvio’s highest dose (108 mg twice daily) over six weeks.Trevi reiterated that topline results are expected in the first half of 2025.Wall Street analysts responded positively to the update:•&nbsp;Jones Research reiterated a ‘Buy’ rating, stating the analysis enhances confidence in the trial’s statistical assumptions, which indicate a high likelihood of demonstrating significant cough reduction.• Needham’s Serge Belanger called the result the “best case outcome,” highlighting it as a de-risking event.&nbsp;He highlighted that&nbsp;the study’s treatment effect size and dropout rates align with initial assumptions, supporting the original design. Needham maintained a ‘Buy’ rating with an $8 price target.• H.C. Wainwright raised its price target to $7.50 from $6, describing the update as a “material positive” for investor sentiment ahead of data readouts.Year-to-date, TRVI stock has gained over 170%, as of the last close,&nbsp; showcasing strong investor interest in the company’s pipeline and prospects.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Stockbroker analyzing financial stock market with reflection on eyeglasses. Photo via Westend61 on Getty Images

Retail Chatter For Trevi Therapeutics Soars After Enrollment Target For Chronic Cough Study Hits 75%

An independent statistician confirmed the sample size following a re-estimation analysis, ensuring that the trial’s design remains statistically robust.

Equity

Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of Haduvio to treat serious neurologically mediated conditions. It includes treatment of chronic pruritus associated with prurigo nodularis and chronic cough in patients with idiopathic pulmonary fibrosis, and levodopa-induced dyskinesia in patients with Parkinson’s disease. The company was founded by Thomas R. Sciascia and Jennifer L. Good in 2011 and is headquartered in New Haven, CT.

Trevi Therapeutics Inc

$ASTS

$RKLB

$BBAI

$NBIS

Which earnings release are you most excited for the week of Nov. 10? 
 
Drop a comment for others.

TRVI
Trevi Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest TRVI News

TRVITrevi Therapeutics Inc